1. |
Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Ron E, Curtis R, Hoffman D A, et al. Multiple primary breast and thyroid cancer. Br J Cancer, 1984, 49(1): 87-92.
|
3. |
Nielsen SM, White MG, Hong S, et al. The breast-thyroid cancer link: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev, 2016, 25(2): 231-238.
|
4. |
Suteau V, Munier M, Briet C, et al. Sex bias in differentiated thyroid cancer. Int J Mol Sci, 2021, 22 (23): 12992. doi: 10.3390/ijms222312992.
|
5. |
Wahdan-Alaswad RS, Edgerton SM, Salem H, et al. Exogenous thyroid hormone is associated with shortened survival and upregulation of high-risk gene expression profiles in steroid receptor-positive breast cancers. Clin Cancer Res, 2021, 27(2): 585-597.
|
6. |
Cao Y, Wang Z, Gu J, et al. Reproductive factors but not hormonal factors associated with thyroid cancer risk: A systematic review and meta-analysis. Biomed Res Int, 2015, 2015, 103515. doi: 10.1155/2015/103515.
|
7. |
Kim EY, Chang Y, Lee KH, et al. Serum concentration of thyroid hormones in abnormal and euthyroid ranges and breast cancer risk: A cohort study. Int J Cancer, 2019, 145(12): 3257-3266.
|
8. |
Zyla LE, Cano R, Gómez S, et al. Effects of thyroxine on apoptosis and proliferation of mammary tumors. Mol Cell Endocrinol, 2021, 538: 111454. doi: 10.1016/j.mce.2021.111454.
|
9. |
Søgaard M, Farkas D K, Ehrenstein V, et al. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. Eur J Endocrinol, 2016, 174(4): 409-414.
|
10. |
Hu X, Wang X, Liang Y, et al. Cancer risk in Hashimoto’s thyroiditis: a systematic review and meta-analysis. Front Endocrinol (Lausanne), 2022, 13: 937871. doi: 10.3389/fendo.2022.937871.
|
11. |
Graceffa G, Scerrino G, Militello G, et al. Breast cancer in previously thyroidectomized patients: which thyroid disorders are a risk factor? Future Sci OA, 2021, 7 (5): FSO699. doi: 10.2144/fsoa-2021-0029.
|
12. |
Rahman S, Archana A, Jan A T, et al. Molecular insights into the relationship between autoimmune thyroid diseases and breast cancer: A critical perspective on autoimmunity and ER stress. Front Immunol, 2019, 10: 344. doi: 10.3389/fimmu.2019.00344.
|
13. |
Pasqual E, Schonfeld S, Morton LM, et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies. J Clin Oncol, 2022, 40(13): 1439-1449.
|
14. |
Wijnen M, van den Heuvel-Eibrink MM, Medici M, et al. Risk factors for subsequent endocrine-related cancer in childhood cancer survivors. Endocr Relat Cancer, 2016, 23(6): R299-R321.
|
15. |
Burt LM, Ying J, Poppe MM, et al. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast, 2017, 35: 122-129.
|
16. |
Kuijpens JLP, Nyklíctek I, Louwman MWJ, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid, 2005, 15(11): 1253-1259.
|
17. |
Tosovic A, Becker C, Bondeson AG, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer, 2012, 131(9): 2126-2133.
|
18. |
Prinzi N, Baldini E, Sorrenti S, et al. Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3 921 patients. Breast Cancer Res Treat, 2014, 144(3): 683-688.
|
19. |
Godlewska M, Banga PJ. Thyroid peroxidase as a dual active site enzyme: Focus on biosynthesis, hormonogenesis and thyroid disorders of autoimmunity and cancer. Biochimie, 2019, 160: 34-45.
|
20. |
Smyth PP. Autoimmune thyroid disease and breast cancer: a chance association? J Endocrinol Invest, 2000, 23 (1): 42-43.
|
21. |
Brandt J, Borgquist S, Almquist M, et al. Thyroid function and survival following breast cancer. Br J Surg, 2016, 103(12): 1649-1657.
|
22. |
Bach L, Kostev K, Schiffmann L, et al. Association between thyroid gland diseases and breast cancer: a case-control study. Breast Cancer Res Treat, 2020, 182(1): 207-213.
|
23. |
Jiskra J, Barkmanova J, Limanova Z, et al. Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep, 2007, 18(6): 1603-1611.
|
24. |
Giustarini E, Pinchera A, Fierabracci P, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol, 2006, 154(5): 645-649.
|
25. |
张宁, 郑鸿, 胡夕春. 血清甲状腺激素水平的检测在乳腺癌患者中的临床意义. 现代肿瘤医学, 2018, 26(23): 3780-3782.
|
26. |
张立, 吴万敏. 乳腺癌患者血清甲状腺激素水平和甲状腺过氧化物酶抗体表达及其临床意义. 中华乳腺病杂志(电子版), 2011, 5(4): 459-465.
|
27. |
Kemal Y, Demirag G, Ekiz K, et al. Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer. Mol Clin Oncol, 2015, 3(3): 629-632.
|
28. |
Farahati J, Roggenbuck D, Gilman E, et al. Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer. Clin Chem Lab Med, 2012, 50(4): 709-714.
|
29. |
孟宪杰, 魏莉, 马小燕. 老年乳腺癌患者甲状腺过氧化物酶抗体表达及临床意义. 中 国老年学杂志, 2015, 35(13): 3627-3629.
|
30. |
中国抗癌协会乳腺癌诊治指南与规范(2019年版). 中国癌症杂志, 2019, 29(8): 609-680.
|
31. |
王伟刚, 田保国, 徐晓琴, 等. 乳腺癌与甲状腺疾病关系的临床研究. 肿瘤研究与临床, 2022, 34(3): 215-220.
|
32. |
Zhao X, Yang G, Zhang W, et al. Age-related risk for second breast cancer and gynecological malignant neoplasms after differentiated thyroid cancer. Endocrine, 2022, 76(2): 385-394.
|
33. |
Chen S, Wu F, Hai R, et al. Thyroid disease is associated with an increased risk of breast cancer: a systematic review and meta-analysis. Gland Surg, 2021, 10(1): 336-346.
|
34. |
Muller I, Barrett-Lee PJ. The antigenic link between thyroid autoimmunity and breast cancer. Semin Cancer Biol, 2020, 64: 122-134.
|
35. |
Bolf EL, Sprague BL, Carr FE. A linkage between thyroid and breast cancer: A common etiology? Cancer Epidemiol Biomarkers Prev, 2019, 28(4): 643-649.
|
36. |
Muller I, Kilburn LS, Taylor PN, et al. TPOAb and thyroid function are not associated with breast cancer outcome: evidence from a large-scale study using data from the taxotere as adjuvant chemotherapy trial (TACT, CRUK01/001). Eur Thyroid J, 2017, 6(4): 197-207.
|
37. |
Chiappa C, Rovera F, Rausei S, et al. Breast cancer and thyroid diseases: analysis of 867 consecutive cases. J Endocrinol Invest, 2017, 40(2): 179-184.
|
38. |
Fiore E, Giustarini E, Mammoli C, et al. Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest, 2007, 30(9): 734-738.
|
39. |
Godlewska M, Krasuska W, Czarnocka B. Biochemical properties of thyroid peroxidase (TPO) expressed in human breast and mammary-derived cell lines. PLoS One, 2018, 13(3): e0193624. doi: 10.1371/journal.pone.0193624.
|
40. |
Godlewska M, Arczewska KD, Rudzińska M, et al. Thyroid peroxidase (TPO) expressed in thyroid and breast tissues shows similar antigenic properties. PLoS One, 2017, 12(6): e0179066. doi: 10.1371/journal.pone.0179066.
|
41. |
Muller I, Zhang L, Giani C, et al. The sodium iodide symporter is unlikely to be a thyroid/breast shared antigen. J Endocrinol Invest, 2016, 39(3): 323-331.
|
42. |
张勇, 余一朗, 单鹏飞, 等. 乳腺癌患者改良根治术后复发转移的相关危险因素分析. 中华普外科手术学杂志(电子版), 2021, 15(4): 418-421.
|
43. |
姚家炳, 翟保平, 贾琳娇, 等. 乳腺癌患者脉管癌栓与临床病理特征及预后的关系. 中华实用诊断与治疗杂志, 2017, 31(9): 872-874.
|
44. |
胡金月, 孙永强. 脉管癌栓与激素受体阳性乳腺癌患者临床病理特征及预后的关系. 临床医学研究与实践, 2019, 4(35): 33-35.
|
45. |
杨丽, 朱荔, 马金平, 等. 乳腺癌前哨淋巴结与非前哨淋巴结转移危险因素分析. 中华肿瘤防治杂志, 2019, 26(22): 1726-1731.
|
46. |
王艳滨, 徐应军, 张文杰. 影响乳腺癌多发性癌灶发生的因素分析. 实用癌症杂志, 2002, 17(2): 184-186.
|
47. |
Muller I, Giani C, Zhang L, et al. Does thyroid peroxidase provide an antigenic link between thyroid autoimmunity and breast cancer? Int J Cancer, 2014, 134(7): 1706-1714.
|